Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $1.91 $2.42 Friday, 10th May 2024 CANF stock ended at $2.09. This is 2.42% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 3.29% from a day low at $2.05 to a day high of $2.12.
90 days $1.91 $2.71
52 weeks $1.81 $3.33

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Aug 10, 2016 $2.21 $2.21 $2.16 $2.18 19 100
Aug 09, 2016 $2.17 $2.22 $2.16 $2.18 36 500
Aug 08, 2016 $2.24 $2.24 $2.17 $2.19 44 600
Aug 05, 2016 $2.14 $2.20 $2.11 $2.14 46 400
Aug 04, 2016 $2.15 $2.16 $2.05 $2.10 36 100
Aug 03, 2016 $2.07 $2.13 $2.06 $2.12 92 300
Aug 02, 2016 $2.07 $2.12 $2.05 $2.07 26 700
Aug 01, 2016 $2.12 $2.14 $2.09 $2.10 30 800
Jul 29, 2016 $2.07 $2.11 $2.05 $2.10 32 000
Jul 28, 2016 $2.12 $2.14 $2.06 $2.07 57 600
Jul 27, 2016 $2.18 $2.18 $2.11 $2.11 16 800
Jul 26, 2016 $2.18 $2.18 $2.08 $2.13 59 300
Jul 25, 2016 $2.14 $2.21 $2.11 $2.13 60 300
Jul 22, 2016 $2.17 $2.19 $2.08 $2.09 68 300
Jul 21, 2016 $2.20 $2.26 $2.16 $2.20 93 700
Jul 20, 2016 $2.17 $2.28 $2.17 $2.21 100 100
Jul 19, 2016 $2.26 $2.26 $2.04 $2.20 128 300
Jul 18, 2016 $2.17 $2.26 $2.15 $2.23 50 400
Jul 15, 2016 $2.17 $2.24 $2.15 $2.17 78 200
Jul 14, 2016 $2.21 $2.25 $2.18 $2.21 52 300
Jul 13, 2016 $2.28 $2.29 $2.19 $2.21 63 600
Jul 12, 2016 $2.39 $2.39 $2.23 $2.28 69 600
Jul 11, 2016 $2.26 $2.40 $2.24 $2.29 72 900
Jul 08, 2016 $2.24 $2.42 $2.24 $2.28 140 600
Jul 07, 2016 $2.27 $2.33 $2.25 $2.25 100 000
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT